- Home
- GLUE
GLUE
Monte Rosa Therapeutics Inc.
as 05-09-2025 3:36pm EST
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $14.33 | AVG Volume (30 days): | 573.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $12.40 | Next Earning Date: | 05-08-2025 |
| Revenue: | $159,487,000 | Revenue Growth: | 14889.38% |
| Revenue Growth (this year): | -10.64% | Revenue Growth (next year): | -27.55% |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leo Chandra P. | GLUE | Director | Mar 24 '25 | Buy | $5.84 | 10,000 | $58,383.00 | 10,000 |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
Associated Press Finance
a day ago
Monte Rosa Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
a day ago
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
11 days ago
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Simply Wall St.
17 days ago
Monte Rosa Therapeutics Insider Ups Holding During Year
GuruFocus.com
2 months ago
Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect
Clinical Trials Arena
2 months ago
Mixed data results for two Monte Rosa molecular glue degraders
MT Newswires
2 months ago
Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.